Edition:
United Kingdom

Dr.Reddy's Laboratories Ltd (REDY.BO)

REDY.BO on Bombay Stock Exchange

2,064.90INR
11:18am BST
Change (% chg)

Rs-24.25 (-1.16%)
Prev Close
Rs2,089.15
Open
Rs2,057.90
Day's High
Rs2,119.00
Day's Low
Rs2,057.40
Volume
136,277
Avg. Vol
100,313
52-wk High
Rs2,788.00
52-wk Low
Rs1,888.00

Select another date:
Photo

Indivior warning on anti-opioid drug competition sends shares tumbling

British drugmaker Indivior warned on Wednesday it would miss its full-year profit target as its best-selling opioid addiction drug faces new competitors in the United States, sending its shares down 37 percent.

Indivior's shares jump 30 pct after U.S. court blocks sale of rival generic

July 16 Indivior Plc's shares soared as much as 30 percent on Monday after a U.S. court blocked India's Dr.Reddy's Laboratories from selling copycat versions of the British drugmaker's bestselling opioid addiction treatment in the United States.

Indivior gets breather after court extends order blocking generic rival

Indivior Plc got a breather on Friday as a U.S. court extended a restraining order blocking a rival from launching a generic version of its bestselling opioid addiction treatment in the United States.

UPDATE 2-Indivior gets breather after court extends order blocking generic rival

* Update on Sublocade will be key to sentiment-Jefferies (Adds share move, analyst comments)

U.S. court extends Indivior's restraining order against Dr. Reddy's generic drug

June 29 British drugmaker Indivior Plc said on Friday a U.S. court extended the restraining order blocking Indian pharmaceutical firm Dr.Reddy's Laboratories from launching a generic version of its bestselling opioid addiction treatment in the United States.

Indivior shares rise after U.S. court order blocks generic rival drug

Shares in drugmaker Indivior rose on Monday after a U.S. Court granted a temporary restraining order blocking Dr. Reddy's Laboratories from launching a generic version of Indivior's best-selling opioid addiction treatment.

Indian shares close slightly higher; SBI, Dr.Reddy's gain on Q4 results

May 22 Indian shares ended slightly higher on Tuesday, driven by gains in Dr. Reddy's Laboratories Ltd and State Bank of India (SBI) following their quarterly results.

UPDATE 1-India's Dr. Reddy's Q4 profit falls 19 pct on U.S. headwinds

May 22 Indian generic drugmaker Dr. Reddy's Laboratories Ltd posted a 19 percent drop in quarterly net profit on Tuesday, missing analysts' estimates, pulled down by headwinds in the U.S. market.

CORRECTED-India's Dr. Reddy's Q4 profit falls about 19 pct, misses estimates

May 22 Indian generic drugmaker Dr. Reddy's Laboratories Ltd posted an about 19 percent fall in quarterly net profit, missing estimates, hurt by headwinds in the U.S. market.

BRIEF-Dr.Reddy's Labs Gets EIR From USFDA For API Mirfield Plant, UK

* GETS ESTABLISHMENT INSPECTION REPORT FROM US FDA FOR API MIRFIELD PLANT, UK Source text for Eikon: Further company coverage:

Select another date: